Post hoc 5-year analysis of 1150 men with metastatic hormone-sensitive prostate cancer: estimated 5-year survival was 66% with enzalutamide plus ADT vs 53% with placebo plus ADT (HR 0.70; nominal p); no new safety signals.
Secondary analysisn = 1,150
Armstrong et al. ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients